BOPA/ISOPP 2019 | Potential role of rituximab in mCRPC

Lisa Holle

Lisa Holle, PharmD, BCOP, FHOPA, University of Connecticut School of Pharmacy, Storrs, CT, reviews a recent case study of a patient with castrate-resistant prostate cancer who responded to treatment for a secondary folliular lymphoma following treatment with rituximab. This interview took place at the International Society of Oncology Pharmacy Practitioners (ISOPP) Symposium 2019, hosted by the British Oncology Pharmacy Association (BOPA), held in London, UK.

Share this video  
Similar topics